Inhaled 5% carbon dioxide during mechanical ventilation in ARDS patients on venovenous ECMO

Phase 3, open-label, single-arm trial of Carbon dioxide in acute respiratory distress syndrome (ARDS) and respiratory failure, sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: Feasibility of adding inhaled 5% carbon dioxide without altering arterial carbon dioxide or pH. Started Mar 2019; status: terminated.